Lung microbiota of patients with ARDS due to coronavirus disease 2019 receiving ECMO

Abstract Diversity of the microbiota, which is essential for lower airway homeostasis, is greatly altered in acute respiratory distress syndrome (ARDS). Extracorporeal membrane oxygenation (ECMO) is the ultimate protective treatment for the lungs of patients with severe ARDS, but little is known abo...

Full description

Saved in:
Bibliographic Details
Main Authors: Yumi Mitsuyama, Kentaro Shimizu, Daisuke Motooka, Hiroshi Ogura, Satoshi Fujimi, Jun Oda
Format: Article
Language:English
Published: Nature Portfolio 2025-07-01
Series:Scientific Reports
Subjects:
Online Access:https://doi.org/10.1038/s41598-025-08664-1
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1849403154694668288
author Yumi Mitsuyama
Kentaro Shimizu
Daisuke Motooka
Hiroshi Ogura
Satoshi Fujimi
Jun Oda
author_facet Yumi Mitsuyama
Kentaro Shimizu
Daisuke Motooka
Hiroshi Ogura
Satoshi Fujimi
Jun Oda
author_sort Yumi Mitsuyama
collection DOAJ
description Abstract Diversity of the microbiota, which is essential for lower airway homeostasis, is greatly altered in acute respiratory distress syndrome (ARDS). Extracorporeal membrane oxygenation (ECMO) is the ultimate protective treatment for the lungs of patients with severe ARDS, but little is known about its effect on the lung microbiota of these patients. To evaluate the effect of ECMO on the lung microbiota of ARDS patients, we performed 16S rRNA and fungal ITS1 profiling and shotgun sequencing on bronchoalveolar lavage fluid (BALF) collected from ARDS patients due to COVID-19. BALF was collected from 13 patients, five of whom underwent ECMO. In all patients, Pseudomonas was the most abundant of the bacteria. The patients with ECMO had more Pseudomonas and more Klebsiella than those without ECMO. The most abundant fungi were unspecified fungi in the patients with ECMO and Emmia lacerata in the patients without ECMO. Alpha diversity of bacteria and fungi did not differ significantly between the two groups. Human betaherpesvirus 5 and human alphaherpesvirus 1 were predominant in all patients, with human betaherpesvirus 5 decreasing over time in the ECMO patients. The patients with ARDS due to COVID-19 receiving ECMO had a different lung microbiota than those not receiving ECMO.
format Article
id doaj-art-9b83b871eddc496e9e67addea843f0ac
institution Kabale University
issn 2045-2322
language English
publishDate 2025-07-01
publisher Nature Portfolio
record_format Article
series Scientific Reports
spelling doaj-art-9b83b871eddc496e9e67addea843f0ac2025-08-20T03:37:20ZengNature PortfolioScientific Reports2045-23222025-07-0115111110.1038/s41598-025-08664-1Lung microbiota of patients with ARDS due to coronavirus disease 2019 receiving ECMOYumi Mitsuyama0Kentaro Shimizu1Daisuke Motooka2Hiroshi Ogura3Satoshi Fujimi4Jun Oda5Department of Traumatology and Acute Critical Medicine, Graduate School of Medicine, The University of OsakaDepartment of Traumatology and Acute Critical Medicine, Graduate School of Medicine, The University of OsakaGenome Information Research Center, Research Institute for Microbial Diseases, The University of OsakaDepartment of Traumatology and Acute Critical Medicine, Graduate School of Medicine, The University of OsakaDivision of Trauma and Surgical Critical Care, Osaka General Medical CenterDepartment of Traumatology and Acute Critical Medicine, Graduate School of Medicine, The University of OsakaAbstract Diversity of the microbiota, which is essential for lower airway homeostasis, is greatly altered in acute respiratory distress syndrome (ARDS). Extracorporeal membrane oxygenation (ECMO) is the ultimate protective treatment for the lungs of patients with severe ARDS, but little is known about its effect on the lung microbiota of these patients. To evaluate the effect of ECMO on the lung microbiota of ARDS patients, we performed 16S rRNA and fungal ITS1 profiling and shotgun sequencing on bronchoalveolar lavage fluid (BALF) collected from ARDS patients due to COVID-19. BALF was collected from 13 patients, five of whom underwent ECMO. In all patients, Pseudomonas was the most abundant of the bacteria. The patients with ECMO had more Pseudomonas and more Klebsiella than those without ECMO. The most abundant fungi were unspecified fungi in the patients with ECMO and Emmia lacerata in the patients without ECMO. Alpha diversity of bacteria and fungi did not differ significantly between the two groups. Human betaherpesvirus 5 and human alphaherpesvirus 1 were predominant in all patients, with human betaherpesvirus 5 decreasing over time in the ECMO patients. The patients with ARDS due to COVID-19 receiving ECMO had a different lung microbiota than those not receiving ECMO.https://doi.org/10.1038/s41598-025-08664-1MicrobiotaECMOARDSMycobiotaViromeCOVID-19
spellingShingle Yumi Mitsuyama
Kentaro Shimizu
Daisuke Motooka
Hiroshi Ogura
Satoshi Fujimi
Jun Oda
Lung microbiota of patients with ARDS due to coronavirus disease 2019 receiving ECMO
Scientific Reports
Microbiota
ECMO
ARDS
Mycobiota
Virome
COVID-19
title Lung microbiota of patients with ARDS due to coronavirus disease 2019 receiving ECMO
title_full Lung microbiota of patients with ARDS due to coronavirus disease 2019 receiving ECMO
title_fullStr Lung microbiota of patients with ARDS due to coronavirus disease 2019 receiving ECMO
title_full_unstemmed Lung microbiota of patients with ARDS due to coronavirus disease 2019 receiving ECMO
title_short Lung microbiota of patients with ARDS due to coronavirus disease 2019 receiving ECMO
title_sort lung microbiota of patients with ards due to coronavirus disease 2019 receiving ecmo
topic Microbiota
ECMO
ARDS
Mycobiota
Virome
COVID-19
url https://doi.org/10.1038/s41598-025-08664-1
work_keys_str_mv AT yumimitsuyama lungmicrobiotaofpatientswithardsduetocoronavirusdisease2019receivingecmo
AT kentaroshimizu lungmicrobiotaofpatientswithardsduetocoronavirusdisease2019receivingecmo
AT daisukemotooka lungmicrobiotaofpatientswithardsduetocoronavirusdisease2019receivingecmo
AT hiroshiogura lungmicrobiotaofpatientswithardsduetocoronavirusdisease2019receivingecmo
AT satoshifujimi lungmicrobiotaofpatientswithardsduetocoronavirusdisease2019receivingecmo
AT junoda lungmicrobiotaofpatientswithardsduetocoronavirusdisease2019receivingecmo